India's Mankind Pharma drops on lower quarterly margins

Mankind Pharma

22/05/2025 07:05

** Mankind Pharma MNKI.NS shares down 3.7% to 2,437.2 rupees

** Stock on track to log worst day in more than 3 months

** Top loser on Nifty pharma index .NIPHARM, which is down 0.8%

** Drugmaker posted smaller-than-expected drop in Q4 consol net profit; EBITDA margins contracted by 200 bps, PAT margins dropped by 580 bps, which analysts attributed to co's restructuring measures

** Co expects domestic sales to normalise from Q2, which is a delay of a quarter versus our prior estimates - Kotak Institutional Equities

** Analysts at Ambit said co's effective integration of BSV Pharma's business, which it acquired in July 2024, is key to MNKI's medium-term growth and margins trajectory

** YTD, stock down 15%

 (Reporting by Manvi Pant in Bengaluru)

 ((Manvi.Pant@thomsonreuters.com; +918447554364;))